Skip to main content
Toggle navigation
Login
Search
Home
Browse by Poster Title
Home
Browse by Poster Title
Browse by Poster Title
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#
Sort by
#
Sort by
Title
P
S-065
Performance Verification and Application of Endogenous Biomarker Coproporphyrin I in the Simcyp™ Simulator V23
Favorite
M-090
Pharmacoequivalence vs Bioequivalence: A role for MIDD analysis in bioequivalence studies
Favorite
T-074
Pharmacokinetic and Exposure-Response Modeling Support Body Surface Area-Based Dosing of Farletuzumab Ecteribulin in Patients with Solid Tumors
Favorite
T-095
Pharmacokinetic Modeling of Prophylactic Dose Rivaroxaban Transfer into Human Milk
Favorite
T-063
Pharmacokinetic-pharmacodynamic (PK-PD) modeling and simulation of a Novel, Directly Acting Antiviral, BDGR-251, in EEEV Infected Mice
Favorite
S-034
Pharmacometric analysis of pharmacokinetics, safety, and efficacy data of migoprotafib in combination with divarasib for KRAS G12C-positive non-small cell lung cancer.
Favorite
T-085
Pharmacometric Modeling of Clazakizumab in Patients Undergoing Maintenance Dialysis
Favorite
M-065
Pharmacometrics and Machine Learning-Based Modeling to Assess the Impact of Vaginal Microbiome on Tenofovir Exposures in the Female Genital Tract of African Women
Favorite
S-064
Physiologically Based Pharmacokinetic Modeling of Quizartinib to Assess Drug-Drug Interaction as an Inhibitor of Breast Cancer Resistance Protein
Favorite
M-088
PK/PD Analysis of the Primary Endpoint for Nipocalimab in Sjögren's Disease
Favorite
T-110
PK/PD Modeling of Dexamethasone in Heart and Lung Tissues in an Animal Model of Cytokine Release Syndrome
Favorite
T-086
PK/PD Modeling Suggests Tumor Heterogeneity Limits Preclinical to Clinical Translation of Enzalutamide in Prostate Cancer
Favorite
T-030
PK/PD/PD Models Enable Quantitative Insights into the Exposure-Efficacy Relationships of Tirzepatide for Treatment of Obstructive Sleep Apnea
Favorite
S-083
PKPD investigation of BI-S across blood-ocular barrier
Favorite
S-077
Population Pharmacokinetic & Exposure-Response Analysis After Subcutaneous Administration of Guselkumab in Pediatric Participants with Moderate to Severe Plaque Psoriasis
Favorite
S-105
POPULATION PHARMACOKINETIC (POPPK) MODELING OF IRINOTECAN AND SN38 IN PARTICIPANTS WITH METASTATIC COLORECTAL CANCER (MCRC) IN PHASE 2 AND 3 STUDIES: A SEQUENTIAL PARENT-METABOLITE MODEL
Favorite
S-020
Population Pharmacokinetic Analysis of Domvanalimab in Patients with Solid Tumors
Favorite
M-069
Population Pharmacokinetic Analysis of Dupilumab in Patients With Chronic Obstructive Pulmonary Disease
Favorite
M-033
Population Pharmacokinetic Analysis of Possible Drug-Drug Interactions between Mouse Double Minute 2 (MDM2) Inhibitor Navtemadlin and the Bruton's Tyrosine Kinase (BTK) Inhibitor Acalabrutinib in Patients with R/R CLL or R/R DLBCL
Favorite
M-103
Population Pharmacokinetic Analysis of QRL-201 in Plasma and CSF in Patients With Amyotrophic Lateral Sclerosis From A First-in-Human Phase 1 Multiple Ascending Dose Escalation Study
Favorite
S-113
Population pharmacokinetic analysis of sertraline in pregnant individuals
Favorite
S-113
Population pharmacokinetic analysis of sertraline in pregnant individuals
Favorite
M-094
Population Pharmacokinetic Analysis of Zimberelimab in Patients with Solid Tumors
Favorite
T-079
Population Pharmacokinetic Analysis to Characterize Pharmacokinetics of Sarilumab in Pediatric Participants with Polyarticular-Course Juvenile Idiopathic Arthritis
Favorite
M-070
Population pharmacokinetic and exposure-response analysis of high-dose methotrexate-associated mucositis in infant patients with acute lymphoblastic leukemia
Favorite
M-070
Population pharmacokinetic and exposure-response analysis of high-dose methotrexate-associated mucositis in infant patients with acute lymphoblastic leukemia
Favorite
T-072
Population pharmacokinetic model-informed dose selection for exogenous hemopexin (CSL889) in patients with sickle cell disease
Favorite
S-084
Population pharmacokinetic modeling of anti-B7H4 antibody-drug conjugate (SGN-B7H4V) in patients with advanced solid tumors from phase 1 study
Favorite
M-010
Population Pharmacokinetic Modeling of Encorafenib and LHY746 In Participants with Solid Tumors in Phase 2 Studies: A Sequential Parent-Metabolite Model
Favorite
M-002
Population Pharmacokinetic Modeling of MEDI7352, a Bispecific Fusion Protein for Dual Targeting of NGF and TNFα, in Patients with Painful Diabetic Neuropathy and Painful Osteoarthritis of the Knee
Favorite
S-098
Population Pharmacokinetic Modeling of Rezpegaldesleukin after Subcutaneous Dosing to Account for Variability Across Multiple Patient Populations with Autoimmune Diseases
Favorite
S-059
Population Pharmacokinetic, Exposure-Response, and Time-To-Event Analyses of Probenecid in Symptomatic, Non-Hospitalized Patients with COVID-19
Favorite
T-080
Population Pharmacokinetic/Pharmacodynamic Modeling and Analysis of Tetrahydrobiopterin and Blood Phenylalanine Response in Adult and Pediatric Patients with Phenylketonuria During Sepiapterin Treatment
Favorite
T-071
Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Size Dynamics in Lorlatinib-treated Patients with Non-small Cell Lung Cancer
Favorite
S-006
Population Pharmacokinetics and Exposure-Response Analysis for TAR-200, an Intravesical Drug Delivery System for Bladder Cancer Treatment
Favorite
M-095
Population Pharmacokinetics and Exposure-response Analysis of Cemsidomide in Patients with Relapsed/Refractory Multiple Myeloma and Non-Hodgkin’s Lymphoma
Favorite
S-047
Population Pharmacokinetics and Exposure-Response Analysis of Nivolumab in Combination with Ipilimumab in Participants with First-Line Unresectable or Advanced Hepatocellular Carcinoma to Support Benefit-Risk Assessment
Favorite
M-054
Population pharmacokinetics and exposure-safety analysis of SGN-STNV (PF-08046055) in patients with locally advanced and/or metastatic solid tumors: Phase-1a/b study
Favorite
M-072
Population Pharmacokinetics and Pharmacodynamic Analysis of MT-4561, a Novel Bromodomain-containing Protein 4 (BRD4) Protein Degrader
Favorite
M-012
Population pharmacokinetics and pharmacodynamics analysis of PF-07328948, a branched-chain ketoacid dehydrogenase kinase inhibitor, in healthy participants
Favorite
S-024
Population Pharmacokinetics of AMG 193 and its Impact on SDMA Inhibition in Patients with Advanced MTAP-deleted Solid Tumors
Favorite
T-094
Population Pharmacokinetics of Brensocatib in Adult and Adolescent Patients with Non-Cystic Fibrosis Bronchiectasis (BE)
Favorite
T-084
Population Pharmacokinetics of Deutetrabenazine in Asian Individuals
Favorite
T-104
Population Pharmacokinetics of Dexmedetomidine in Neonates with Hypoxic-Ischemic Encephalopathy Undergoing Therapeutic Hypothermia: Insights from a Prospective Real-World Study
Favorite
S-055
Population Pharmacokinetics of Elranatamab in Chinese Patients with Relapsed or Refractory Multiple Myeloma using PRIOR Approach
Favorite
T-111
Population Pharmacokinetics of Levocetirizine in Children with Uncontrolled Allergic Asthma: An Ongoing Study
Favorite
T-046
Population Pharmacokinetics of Subcutaneous Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Favorite
T-082
Population PK and PK/PD Modeling of Apitegromab in Spinal Muscular Atrophy Patients
Favorite
S-003
Population PK Modeling of Ziftomenib and its Metabolites in Healthy Subjects and in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Favorite
S-115
Population PK/PD Modeling to Optimize Dosing of BIIB107, an Anti-Alpha-4 Integrin Monoclonal Antibody
Favorite
S-008
Population PK-RO-IgG Modeling of Nipocalimab in Patients with Sjögren's Disease
Favorite
T-033
Practical PK/PD Modeling of Lymphocytes and CD4+ T Cells in HIV Patients Treated with the Nucleoside Reverse Transcriptase Translocation Inhibitor (NRTTI) Islatravir
Favorite
S-117
Predicting Clinical Mosunetuzumab CD20 Receptor Occupancy using a Minimal Physiologically–Based Pharmacokinetic (mPBPK) Modeling Approach
Favorite
M-035
Predicting Improved Weaning Strategies for Mechanical Ventilation with a Physiologically-Based Mechanistic Model
Favorite
T-039
Predicting Tumor Growth Dynamics and Overall Survival with Deep Learning Model
Favorite
M-047
Prediction of human pharmacokinetic profiles of Glyph(TM) platform prodrugs using animal and human data via a semi-mechanistic pharmacokinetic model
Favorite
M-001
Prediction of Percent Free Nerve Growth Factor Suppression following Administration of MEDI7352, a Bispecific Fusion Protein for Dual Targeting of NGF and TNFα, in Patients with Painful Diabetic Neuropathy and Osteoarthritis
Favorite
T-055
Prospective Physiologically Based Pharmacokinetic Modeling Predictions of First-in-Patient Study PK: Examples and Application
Favorite
S-013
Proteosis-Targeting Chimera Efficacy Prediction Using a Deep-Learning–QSP Model
Favorite
